Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8473538 | Journal of Molecular and Cellular Cardiology | 2018 | 27 Pages |
Abstract
AS105 is a novel, highly potent ATP-competitive CaMKII inhibitor. In vitro, it effectively reduced SR Ca2+-leak, thus improving SR Ca2+-accumulation and reducing cellular arrhythmogenic correlates, without negatively influencing excitation-contraction coupling. These findings further validate CaMKII as a key target in cardiovascular disease, implicated by genetic, allosteric inhibitors, and pseudo-substrate inhibitors.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
Stefan Neef, Alexander Steffens, Patricia Pellicena, Julian Mustroph, Simon Lebek, Katharina R. Ort, Howard Schulman, Lars S. Maier,